GSK and Moderna slide on RSV vaccine CDC updates
GSK PLC (LSE:GSK, NYSE:GSK) shares fell 6% after US authorities recommended restrictions on doses of any respiratory syncytial virus (RSV) vaccine.…
24,545€
2,85%
Echtzeit-Aktienkurs Pfizer Inc.
Bid:
Ask:
Nachrichten zur Pfizer Inc. Aktie
CDC advisors narrow age recommendation for RSV shots in U.S.
Last year, GSK and Pfizer went head-to-head with rival RSV shots for all adults aged 60 and over, who could…
Moderna says its RSV shot is 50% effective after 18 months
In their clinical trials, GSKs RSV vaccine Arexvy was 78% effective in preventing severe RSV over a second year and…
Is Pfizers Pain Sarepta Therapeutics Gain? Dont Bet on It.
One companys negative results can increase scrutiny of anothers work.…
Pfizers Working on the Next Wegovy, but Can It Beat Novo Nordisk?
This is a matchup that the latecomer might not be able to win.…
Pfizer CEO reveals new weight loss drug mechanism in works
…
Global Contraceptive Drugs Market Size To Worth USD 40.08 Billion By 2033 | CAGR Of 8.02%
The Global Contraceptive Drugs Market Size was Valued at USD 18.53 Billion in 2023 and the Worldwide Contraceptive Drugs Market…
Pfizer (PFE) Stock Sinks As Market Gains: Heres Why
Pfizer (PFE) closed at $27.99 in the latest trading session, marking a -1.3% move from the prior day.…
Global Parkinson’s Disease Treatment Market Size To Worth USD 9.14 Billion By 2033 | CAGR Of 6.41%
The Global Parkinsons Disease Treatment Market Size was Valued at USD 4.91 Billion in 2023 and the Worldwide Parkinsons Disease…
UK Government Snubs GSK in Favor of Pfizer’s Rival RSV Shot
GSK Plc has lost out to Pfizer Inc. on a contract to supply millions of doses of its blockbuster RSV…
Pfizer: Seriously Undervalued At Peak Pessimism
…
Investing for the Next 12 Months? Buy These
If investors expect interest rates to hold until next year, they should consider dividend-yielding stocks like Altria (NYSE: MO), Bristol…
AKTIONÄR-Alt-Empfehlung Sarepta: "Homerun" – Aktie explodiert – Pfizer schaut in die Röhre
Die Biotech-Gesellschaft Sarepta Therapeutics fokussiert sich seit vielen Jahren auf die Entwicklung von gentherapeutischen Ansätzen zur Behandlung von Duchenne Muskeldystrophie…
The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
Pfizer, Johnson & Johnson and Eli Lilly are part of the Zacks top Analyst Blog.…
Global Anal Fissure Treatment Market Size To Exceed USD 1986.1 Million By 2033 | CAGR Of 5.51%
The Global Anal Fissure Treatment Market Size was Valued at USD 1161.3 Million in 2023 and the Worldwide Anal Fissure…
Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies in 2024
Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking…
Pfizer sued in Kansas over COVID-19 vaccine
…
Impfstoff: US-Bundesstaat verklagt Pfizer
Verschwiegene Risiken, falsche Behauptungen zur Sicherheit und Unterdrückung kritischer Stimmen auf Social Media - die Klage, die der US-Bundesstaat Kansas…
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
…
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
These two pharma stocks are beloved by income investors.…
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb @themotleyfool #stocks $PFE $BMY
These two pharma stocks are beloved by income investors.…
Pfizer Stock: The Reversal Should Keep Going
…
Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit By Reuters
Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit…
Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%
The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…
Pharma Stock Roundup: FDA Panel Endorses LLYs Donanemab, PFEs DMD Therapy Study Fails
An FDA panel endorses Eli Lillys (LLY) Alzheimers disease drug, donanemab. Pfizers (PFE) DMD study on investigational gene therapy fails.…
Sarepta Therapeutics gains as Pfizer failure removes overhang By Investing.com
Sarepta Therapeutics gains as Pfizer failure removes overhang…
Pfizer: Studienrückschlag dürfte die Aktie kurzfristig weiter ausbremsen - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Pfizer-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Pfizer Inc. (ISIN: US7170811035,…
Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon
…
Pfizer: Rückschlag!
Der amerikanische Pharma-Riese muss einen weiteren herben Dämpfer hinnehmen. In einer klinischen Phase-3-Studie konnte Pfizer mit einer potenziellen Gentherapie zur…
Pfizer: Rückschlag!
Der amerikanische Pharma-Riese muss einen weiteren herben Dämpfer hinnehmen. In einer klinischen Phase-3-Studie konnte Pfizer mit einer potenziellen Gentherapie zur…
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Pfizers (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with…
Global Prostate Health Market Size To Worth USD 78.03 Billion By 2033 | CAGR Of 9.12%
The Global Prostate Health Market Size was Valued at USD 32.6 Billion in 2023 and the Worldwide Prostate Health Market…
Pfizer: Deal mit Flagship Pioneering - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Pfizer-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Pfizer Inc. (ISIN: US7170811035,…
Pfizer: Neuer Adipositas-Deal
Der Pharma-Riesen Novo Nordisk und Eli Lilly haben dem wachsenden Markt für Adipositas-Medikamente weiter fest im Griff. Mit Übernahmen brachten…
Pfizer: Neuer Adipositas-Deal
Der Pharma-Riesen Novo Nordisk und Eli Lilly haben dem wachsenden Markt für Adipositas-Medikamente weiter fest im Griff. Mit Übernahmen brachten…
GSK, Pfizer to appeal Delaware ruling that allowed trials for thousands of Zantac cases
…
Pfizer Inc. (PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
…
Modernas combination Covid, flu vaccine is more effective than existing shots in late-stage trial
Moderna is the first company to release positive phase three data on a Covid and flu combination shot, giving it…
Pfizer: 3 Gründe für die Underperformance der Dividenden-Aktie
Die Aktie des Pharma-Riesen Pfizer läuft seit einigen Quartalen der Peergroup hinterher. Merck & Co ist inzwischen mehr als doppelt…
Pfizer: 3 Gründe für die Underperformance der Dividenden-Aktie
Die Aktie des Pharma-Riesen Pfizer läuft seit einigen Quartalen der Peergroup hinterher. Merck & Co ist inzwischen mehr als doppelt…
Want $1,000 in Dividend Income? Heres How Much Youd Have to Invest in Pfizer Stock.
Pfizer is a cheap buy with a mouthwatering yield.…
FDA approves GSKs RSV vaccine for high-risk adults ages 50 to 59, expanding shots reach
The FDAs expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and…
Thinking Of Buying Pfizer For Its 5.8% Dividend Yield? Consider This Alternative Option Instead
…
Pfizer: Surging Cancer Rates Will Boost Revenues
…
Pfizer: Too Early For A Turnaround
…
Pfizer: Too Cheap To Miss Out
…
Updated Covid-19 Vaccine Targeting JN.1 Recommended By FDA Panel
An FDA panel recommended that Moderna, Pfizer-BioNTech, and Novavax should develop new Covid-19 vaccines that target the JN.1 variant of…
FDA Panel Recommends New COVID Vaccines For JN.1 Lineage By Fall
Drug manufactures Moderna, Pfizer and Novavax said they expect the new vaccines will be available this fall in time for…
Why Things Could Get Worse for Pfizer Stock Before They Get Better
Investors shouldnt expect a big improvement in Pfizers financials this year.…
Why Things Could Get Worse for Pfizer Stock Before They Get Better @themotleyfool #stocks $PFE
Investors shouldnt expect a big improvement in Pfizers financials this year.…